Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 30, 2008 Brian Lawler	Idenix Aims for a Comeback This drugmaker may be down, but it's not yet out.
The Motley Fool September 28, 2007 Brian Orelli	Idenix Axes Ailing Initiatives The small drug developer drops its hepatitis B program, deciding instead to focus on its HCV and HIV drug development. Investors, take note.
The Motley Fool July 16, 2007 Brian Lawler	Idenix Gets Stopped It's been a bad two months for Idenix Pharmaceuticals. First, negative data for its hepatitis drug candidate, valopicitabine; now the FDA has put a stop to all testing of the drug.
The Motley Fool December 2, 2011 Anders Bylund	Idenix Pharmaceuticals Shares Surged: What You Need to Know Shares of biotech firm Idenix Pharmaceuticals jumped as much as 11.9% on higher-than-average trading volume.
The Motley Fool October 27, 2011 Sean Williams	Idenix Pharmaceuticals Shares Popped: What You Need to Know Shares of biopharmaceutical company Idenix Pharmaceuticals jumped as much as 26% earlier in the trading session before paring the majority of its gains despite any company-specific news.
The Motley Fool September 8, 2010 Brian Orelli	You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win.
The Motley Fool June 7, 2006 Stephen D. Simpson	Novartis Can't Say No The Swiss drug giant signs more deals to boost its pipeline. Investors, here is a strong company in a weak sector that's still somewhat undervalued -- not exactly the worst story of the week.
The Motley Fool March 29, 2006 Stephen D. Simpson	Novartis Bulks Up Its Pipeline The Swiss drug giant once again pays up to add trial candidates to its portfolio. Investors, take note.
The Motley Fool June 15, 2007 Brian Lawler	Idenix Gets Knocked Shares of Idenix drop slightly after the drug developer released clinical trial results this week.
Fast Company December 2005	Brilliant Biotech Our Innovation Scorecard takes a look at biotechnology, one of the hottest industries around, and comes up with four companies to watch.
The Motley Fool August 10, 2010 Ryan McBride	Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive.
Pharmaceutical Executive May 1, 2005	Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short.
The Motley Fool November 8, 2007 Brian Lawler	Idenix Reels Itself In The small-cap drug developer cuts expenditures in the third quarter when sales of their hepatitis treatment don't materialize as quickly as hoped. Investors, take note.
The Motley Fool April 19, 2005 Charly Travers	A Rising Star in Biotech Idenix is following a proven path to success: novel drug development. This is one biotech to keep on your watch list for the next year.
Chemistry World June 12, 2014 Philli Broadwith	Merck & Co bolsters hepatitis C pipeline with Idenix acquisition US drug firm Merck & Co has agreed to buy hepatitis C specialist Idenix for $3.85 billion.
The Motley Fool November 11, 2010 Brian Orelli	ATTRACTing Clinical Trial Failure Let's not make it a habit, Novartis. Novartis is dropping development of lung-cancer treatment ASA404 after a second failed phase 3 trial.
Pharmaceutical Executive July 1, 2012	Emerging Pharma Leaders 2012 Meet 2012's Emerging Pharma Leaders. Can these 15 global trend setters set the mark on their time in history by doing better with less while tapping new opportunities from science and technology to build competitive scale?
Pharmaceutical Executive September 1, 2010	Explaining the Drug Drought Industry needs to engage in a broader public debate on ways to rekindle the innovative engine in new drug discovery and development.
The Motley Fool October 31, 2011 Brian Orelli	Gunning for the Leaders Hepatitis C drugs take center stage.
Pharmaceutical Executive June 1, 2011	Emerging Pharma Leaders 2011 Meet 2011's Emerging Pharma Leaders. Can these 30 trendsetters build competitive scale from scarcity?
The Motley Fool October 5, 2010 Brian Orelli	You Should Have Seen this FDA Rejection Coming This hepatitis C treatment was marked for failure.
Bio-IT World November 2005 Mark D. Uehling	The Unstoppable Swiss At a time when other pharmaceutical giants struggle to justify pediatric uses of their medicines, or to defend themselves against thousands of lawsuits, Novartis has one of the safest and strongest pipelines in the industry.
The Motley Fool January 9, 2012 Travis Hoium	Idenix Pharmaceuticals Shares Jumped: What You Need to Know Shares of Idenix Pharmaceuticals got a positive diagnosis today and climbed 43% after the company released positive data for its hepatitis C drug.
The Motley Fool September 23, 2010 Brian Orelli	Ugly Side Effects Won't Derail This Drug Side effects don't matter much when there are no other treatment options, as in Cushing's disease.
The Motley Fool October 23, 2006 Brian Lawler	No Slowing Novartis The Swiss pharmaceutical company shows strength in nearly all its divisions. Novartis looks like a good investment for risk-adverse investors searching for a large-cap pharma stock.
Bio-IT World May 2006 G. Steven Burrill	Biotech Turns in Mixed Q1 Performance Biotech closed out a rough month of March, but this did not take the shine off the exceptional performance of the mid- and small-cap biotech companies.
Pharmaceutical Executive March 12, 2012 William Looney	Novartis: LEADing in Emerging Markets With growth as its guiding light, Novartis has big plans for the emerging markets. CEO Joe Jimenez tells us what it will take the company to best the competition.
The Motley Fool September 24, 2010 Brian Orelli	So Long and Thanks for All the Drug Candidates Alnylam and Novartis end their five-year partnership.
Chemistry World April 25, 2014 Andy Extance	$25bn-plus trade sharpens pharma giants' focus Three leading pharmaceutical firms are set to exchange business segments valued at over $25 billion, in deals affecting at least 14,000 employees.
Pharmaceutical Executive November 1, 2008	No Ordinary Joe It's been a year since consumer marketing master Joe Jimenez took over the top spot at Novartis Pharma. How's he faring?
The Motley Fool October 19, 2007 Brian Lawler	Schering's Gain Is Only a Mild Headache for Vertex Schering-Plough's strong phase 2 clinical results of its hepatitis C virus drug candidate send shares of competitor Vertex down.
The Motley Fool June 4, 2010 Brian Orelli	This Cancer Drug's on a Roll Novartis' Afinitor scores another win.
BusinessWeek June 11, 2009 Kerry Capell	Novartis: Radically Remaking Its Drug Business CEO Dan Vasella's growth mantra for Novartis is follow the science, not the financials.
The Motley Fool July 7, 2010 Dave Mock	A Big Upgrade for Novartis This bullish call comes from more than just one analyst.
The Motley Fool January 20, 2005 Stephen D. Simpson	Novartis Posts a Swiss Miss The Swiss drug giant has a strong pipeline, but moderate growth and high valuation suggest little room for error.
The Motley Fool December 30, 2008 Brian Orelli	A Shot in the Arm for Novartis' Pipeline The company picks up the rights to a vaccine that fights a virus.
The Motley Fool March 3, 2011 Brian Orelli	3 Cheers for an FDA Rejection German drugmaker Merck said that the Food and Drug Administration had turned down its multiple sclerosis drug cladribine. The pill would have competed with Novartis' Gilenya, which gained FDA approval last year.
Pharmaceutical Executive December 1, 2006	Thoughtleader: Thomas Ebeling, Novartis The Next Big Thing: An interview with the pharma's CEO, who has witnessed tremendous financial and scientific growth at the company and is on the brink of his next major milestone.
Chemistry World January 6, 2015 Sarah Houlton	Riding new waves Global annual spending on medicines is set to top $1 trillion for the first time in 2014, having ended 2013 just shy of that figure at $989 billion.
Pharmaceutical Executive October 1, 2011 Daniel Vasella	Heart of Success: Patient-Centric R&D Drug discovery must remain a core competency of industry. The future success of individual companies will be tightly linked to success in R&D.
Pharmaceutical Executive December 1, 2006	Pipeline 32 compounds that are the early fruit of pharma's investment in targeted drug design.
Nurse Practitioner December 2009 Gujral & Collantes	Understanding Viral Hepatitis: A guide for primary care Recent advancements in the field of genomics and proteomics technology have given researchers and clinicians more insight on disease pathogenesis and helped create more tailored approaches to the treatment of these conditions.
The Motley Fool August 29, 2011 Anders Bylund	Idenix Pharmaceuticals' Shares Popped: What You Need to Know Shares of viral-disease medication developer Idenix Pharmaceuticals climbed 10.9% on vanishingly thin trading volume.
The Motley Fool December 5, 2011 Alexander Crawford	Ending HIV/AIDS: Hedge Funds Believe in These 5 Companies Do you think these companies will contribute to a cure?
Bio-IT World August 18, 2004 Mark D. Uehling	Master of the EDC Universe An interview with Sylva Collins, global head of advanced clinical systems at Novartis, who in the case of electronic data capture (EDC), proved to the pharmaceutical industry that technology could be transformative in clinical trials.
The Motley Fool January 9, 2012 Brian Orelli	3 Reasons Hep C Premiums Might Not Last Careful what you wish for.
The Motley Fool May 28, 2010 Brian Orelli	This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope.
The Motley Fool March 20, 2008 Brian Lawler	Gilead Not Slowing Gilead Sciences gets a new approval for a drug.
The Motley Fool April 17, 2008 Brian Lawler	The End for (Another) Hepatitis C Drug Candidate ViroPharma stops development of its compound after data showed it may hurt the liver.
The Motley Fool September 20, 2005 Brian Gorman	Novartis Stays Focused New developments at the drug giant suggest the company is on track. Investors, take note.